At the conclusion of their cycle, hematocrit concentrations had increased by 3%-point in contrast with baseline. The rise was not connected with for a longer time use or increased AAS dose. A basis for this may be that, further than a particular level of androgenic activity, no more boost of hematocrit occurs: a ‘ceiling influence’. Notably, wh